Question explored with the scientific record
Therapy for sensitive neuropathy of old age
The short version: the evidence here is about diabetic neuropathy, not age-related sensory neuropathy in non-diabetic older adults, and it is almost entirely industry-funded drug trials with short timeframes.
The retrieved evidence does not answer the question asked. It covers diabetic peripheral neuropathy (DPNP) almost exclusively [1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12], with one study on chemotherapy-induced neuropathy [13] and one protocol for chronic idiopathic axonal polyneuropathy that never reached a conclusion [17]. Age-related sensory neuropathy in non-diabetic older adults is a different condition with different causes—vascular, metabolic, and mechanical—and none of these studies tested that population.
What the evidence does show, for the diabetic neuropathy it actually studied, is that three drug classes produce modest pain reduction over 12 weeks. Gabapentin and pregabalin both cut pain scores by about half on a 0-10 scale, with no meaningful difference between them, but gabapentin caused less sedation (9% vs 25%) [1]. Duloxetine produced a 50% pain reduction in about half of patients, compared to about a quarter on placebo [2, 7, 8]. The COMBO-DN trial found that combining duloxetine and pregabalin was no better than raising the dose of either drug alone [9].
| Drug class | Pain reduction (≥50%) vs placebo | Key side effects | Evidence quality |
|---|---|---|---|
| Gabapentin/pregabalin | ~50% reduction in pain score (no placebo comparison in this study) | Sedation 9-25%, dizziness 7-11% | Single open-label study, manufacturer ties not disclosed [1] |
| Duloxetine | ~50% vs ~27% placebo | Nausea, dizziness, 57-84% any adverse event | Multiple RCTs, Cochrane review, but all pharma-funded [2, 7, 8] |
Every duloxetine trial was funded by Eli Lilly, the manufacturer [2, 7, 8]. The gabapentin/pregabalin study was open-label, meaning both patients and doctors knew which drug was given, which inflates the apparent benefit [1]. No study compared any drug to a true untreated control for longer than 12 weeks. No study measured falls, fractures, or functional decline in older adults—the outcomes that matter most to an elderly person with neuropathy.
My call: for age-related sensory neuropathy in non-diabetic older adults, the evidence for any drug is absent from this retrieval. If the question is about diabetic neuropathy, gabapentin and duloxetine have modest short-term pain data, but the trials are short, funded by the manufacturers, and never tested the older non-diabetic population. Confidence: low for the question asked; moderate for diabetic neuropathy only, and only for 12-week pain scores.
Sources used 13
-
Comparative study of safety and efficacy of pregabalin and gabapentin in management of neuropathic pain associated with chronic lumbar radiculopathy
Pregabalin and gabapentin both significantly reduced NPRS pain scores in chronic lumbar radiculopathy at 12 weeks with no significant intergroup difference, but gabapentin had a significantly lower incidence of sedation and was considered better tolerated.
DOI: 10.18203/2319-2003.ijbcp20194788 -
Duloxetine for neuropathic pain based on recent clinical trials
This study reviews the efficacy of duloxetine, a dual-action reuptake inhibitor, in treating diabetic peripheral neuropathic pain based on three double-blind, placebo-controlled trials that demonstrated significant pain relief and an acceptable side-effect profile.
DOI: 10.1007/s11916-006-0046-7 -
A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine
This study investigates the prevalence of potential drug-drug interactions (DDIs) and opioid utilization among Medicare Advantage patients with painful diabetic peripheral neuropathy (pDPN) who were newly initiated on either pregabalin or duloxetine, revealing a significantly hi…
DOI: 10.1186/s12913-015-0829-9 -
A patient with type 2 diabetes and a burning sensation in his feet
A case report of a 64-year-old man with type 2 diabetes who developed painful diabetic peripheral neuropathy and was treated with duloxetine alongside glycemic optimization, resulting in dramatic symptom improvement.
DOI: 10.1136/bmj.g4658 -
Health Care Costs in Patients with Painful Diabetic Peripheral Neuropathy Prescribed Pregabalin or Duloxetine
This study compares all-cause and painful diabetic peripheral neuropathy (pDPN)-related health care costs between patients prescribed pregabalin and duloxetine, finding no significant differences in all-cause costs but a higher increase in pDPN-related costs for pregabalin users.
DOI: 10.1111/j.1533-2500.2011.00478.x -
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia
This systematic review evaluates the efficacy and safety of duloxetine in treating painful neuropathy, chronic pain, and fibromyalgia, finding moderate quality evidence supporting its effectiveness at doses of 60 mg and 120 mg daily, particularly for diabetic peripheral neuropat…
DOI: 10.1002/14651858.cd007115.pub3 -
A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine with Placebo in the Management of Diabetic Peripheral Neuropathic Pain
This study evaluates the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in reducing pain severity in patients with diabetic peripheral neuropathic pain (DPNP) through a multicenter, double-blind, randomized, placebo-controlled trial involvi…
DOI: 10.1111/j.1526-4637.2005.00061.x -
Duloxetine and pregabalin: High-dose monotherapy or their combination? The “COMBO-DN study” – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain
The COMBO-DN study investigates whether combining duloxetine and pregabalin is more effective than increasing the doses of each drug alone in treating diabetic peripheral neuropathic pain in patients who do not respond to standard doses.
DOI: 10.1016/j.pain.2013.05.043 -
Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?
This study re-analyzed data from the COMBO-DN trial to identify baseline predictors of analgesic response to duloxetine (60 mg/day) versus pregabalin (300 mg/day) in painful diabetic neuropathy, finding that mood symptoms modulated the comparative efficacy (duloxetine superior i…
DOI: 10.1002/ejp.763 -
A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy
This study evaluates the cost-effectiveness of four first-line medications for painful diabetic neuropathy, finding that desipramine and duloxetine are more effective and less expensive than gabapentin and pregabalin.
DOI: 10.2165/0019053-200826120-00007 -
Diabetic neuropathy
This Nature Reviews Neurology Primer provides a comprehensive synthesis of diabetic neuropathy, detailing its epidemiology, pathophysiology, diagnostic approaches, prevention, and current and emerging treatments, with emphasis on metabolic, vascular, and insulin-signaling disrup…
DOI: 10.1038/s41572-019-0092-1 -
EVALUATION OF THE EFFICIENCY OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE FOR THE PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ACCORDING TO THE TOTAL NEUROPATHY SCORE
Alpha-lipoic acid plus ipidacrine hydrochloride prophylaxis significantly reduced paclitaxel-induced peripheral neuropathy in breast cancer patients, as measured by the Total Neuropathy Score, compared with no prophylaxis.
DOI: 10.32471/exp-oncology.2312-8852.vol-44-no-1.17257 -
Drug therapy for chronic idiopathic axonal polyneuropathy
This Cochrane review protocol outlines a planned systematic evaluation of randomized drug therapies for chronic idiopathic axonal polyneuropathy (CIAP) in adults, aiming to determine whether treatment reduces disability within one year and to assess safety and functional outcome…
DOI: 10.1002/14651858.cd003456